Hypertension, also known as high blood pressure, is one of the leading causes of global cardiovascular mortality. If left untreated, high blood pressure can lead to several pathologic changes in the cardiovascular system such as left ventricular hypertrophy and fibrosis. Angiotensin-converting enzyme inhibitors (ACEi) are a key component of the recommended treatment for hypertension and against heart attacks. ACEi also promote the release of Ac-SDKP (tetrapeptide N-acetyl-seryl-aspartyl-lysyl-proline), an anti-fibrotic marker that blocks the formation of scar tissue.

In this application note, discover how the Ac-SDKP ELISA kit from Bertin Bioreagent allows accurate measurements of Ac-SDKP peptide levels in blood samples.

Read the application note
Access the webstore